House dust mite sublingual-swallow immunotherapy in perennial rhinitis: a double-blind, placebo-controlled Iranian study.
R.F. Hoseini 1, F. Jabbari 1, A. Rezaee 2, H. Rafatpanah 2, H. Yousefzadeh 3, N. Ariaee 1, H. Sadri 3
1 Allergy Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Allergy and Clinical Immunology, Shahid Bahonar Hospital, Alborz University of Medical Sciences, Karaj, Iran
Sensitivity to house dust mite allergens in the development of allergic rhinitis has a key role. In this study, the clinical and immunological effects of high dose Dermatophagoides farinae sublingual immunotherapy (SLIT) versus placebo were compared. Forty poly-sensitized patients, ages 6-33 years, with allergic rhinitis and positive allergic reaction to the mites were enrolled in the study. Twenty-one patients were placed in the SLIT group and 19 in the placebo group. Expression levels of IL-10, TGF-β, FOXP3 and IL-17 were measured by using real-time PCR before and after the administration of sublingual immunotherapy. Clinical efficacy was estimated by the reduction rate of symptom/medication scores in the SLIT group compared with placebo treatment. After 6 months of SLIT, TGF-β expression levels were increased compared to pre-treatment (P < 0.05). SLIT with D. Farinae extract is an effective treatment for poly-sensitized patients with allergic rhinitis. TGF-β mediated T-cell suppression may be an important mechanism in the first 6 months of SLIT.